JMP Securities Raises Larimar Therapeutics (NASDAQ:LRMR) Price Target to $25.00

Larimar Therapeutics (NASDAQ:LRMR – Free Report) had its price objective hoisted by JMP Securities from $17.00 to $25.00 in a research report report published on Tuesday morning, Benzinga reports. They currently have a market outperform rating on the stock. Separately, Citigroup raised shares of Larimar Therapeutics from a neutral rating to a buy rating and […]

Leave a Reply

Your email address will not be published.

Previous post Wedbush Lowers G1 Therapeutics (NASDAQ:GTHX) Price Target to $4.00
Next post IAC (NASDAQ:IAC) Price Target Raised to $70.00